References
[1]. Chen YP, Chan ATC, Le QT, et al., Nasopharyngeal carcinoma.
Lancet. 2019; 394(10192):64–80.
[2]. Li Y, Xu T, Qian W, et al. Radiation-induced nasopharyngeal
ulcers after intensity modulated radiotherapy in primary nasopharyngeal
carcinoma patients: a dose-volume-outcome analysis. Oral Oncol. 2018;
84:1-6.
[3].Wang FZ,Sun QQ, Jiang CE, et al.Additional induction
chemotherapy to concurrent chemotherapy and intensity-modulated
radiotherapy with or without nimotuzumab in first-line treatment for
locoregionally advanced nasopharyngeal carcinoma: a propensity score
matched analysis.Journal of Cancer.2018; 9(3): 594-603.
[4]. Zhang XX, Ma L, Wang JL, et al. Management of oral mucositis in
patients with head and neck cancer receiving chemoradiotherapy and/or
molecular targeted therapy. Chin J Otorhinolaryngol Head Neck Surg.
2011; 46(6):505-508.
[5]. Du L, Zhang XX, Ma L, et al. Clinical study of nasopharyngeal
carcinoma treated by helical tomotherapy in China: 5-year outcomes.
Biomed Res Int. 2014; 980767.
[6]. Zheng L, Yan S, Yan D, et al. Fatal bleeding in a
nasopharyngeal carcinoma patient after concurrent chemoradiation plus
cetuximab: a case report. Onco Targets Ther. 2013; 6:703-706.
[7]. Zhang X, Wang J, Wu W, et al. Efficacy and safety of combined
radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ
preservation in patients with locally advanced hypopharyngeal
carcinomas. Curr Cancer Drug Targets. 2014; 14(6):589-598.
[8]. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation
Therapy Oncology Group (RTOG) and the European Organization for Research
and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys.
1995;31(5):1341-1346.
[9]. Yousem DM, Hatabu H, Hurst RW, et al. Carotid artery invasion
by head and neck masses: prediction with MR imaging. Radiology. 1995;
195(3):715–720.
[10]. Wang ZQ, Mei Q, Li JB, et al. The long-term survival of
patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT
with or without Nimotuzumab: a propensity score-matched analysis. BMC
Cancer. 2019; 19(1):1122.
[11]. Slevin F, Pan S, Mistry H, et al. A multicentre UK study of
outcomes of nasopharyngeal carcinoma treated with intensity-modulated
radiotherapy ± chemotherapy. Clin Oncol (R Coll Radiol). 2020;
32(4):238-249.
[12]. Shen C, Lu JJ, Gu Y, et al.
Prognostic impact of primary tumor
volume in patients with nasopharyngeal carcinoma treated by definitive
radiation therapy. Laryngoscope. 2008; 118(7):1206-1210.
[13]. Wu RK, Chen ZQ, Chen YL, et al. Risk factors, signs and
prevention of massive bleeding in patients with nasopharyngeal carcinoma
after radiotherapy. Internal Medicine. 2017; 12(3):392-394.(in China)
[14]. Yamazaki H, Ogita M, Himei K, et al.
Carotid blowout syndrome in pharyngeal cancer patients treated by
hypofractionated stereotactic re-irradiation using CyberKnife: a
multi-institutional matched-cohort analysis. Radiother Oncol. 2015;
115(1):67-71.
[15]. Cheng KY, Lee KW, Chiang FY, et al. Rupture of
radiation-induced internal carotid artery pseudoaneurysm in a patient
with nasopharyngeal carcinoma–spontaneous occlusion of carotid artery
due to long-term embolizing performance. Head Neck. 2008;
30(8):1132-1135.
[16]. Zheng LY, Yan SX, Yan DF, et al. Fatal bleeding in a
nasopharyngeal carcinoma patient after concurrent chemoradiation plus
cetuximab: a case report. Onco Targets Ther. 2013; 6:703–706.
[17]. Teo PM, Leung SF, Lee WY, et al. Intracavitary brachytherapy
significantly enhances local control of early T-stage nasopharyngeal
carcinoma: the existence of a dose-tumor-control relationship above
conventional tumoricidal dose. Int J Radiat Oncol Biol Phys. 2000;
46(2):445-458.
[18]. Dionisi F, Fiorica F, D’Angelo E, et al. Organs at risk’s
tolerance and dose limits for head and neck cancer re-irradiation: a
literature review. Oral Oncol. 2019; 98:35–47.
[19]. Du L, Zhang XX, Feng LC, et al. Treatment of nasopharyngeal
carcinoma using simultaneous modulated accelerated radiation therapy via
helical tomotherapy: a phase II study. Radiol Oncol. 2016;
50(2):218-225.
[20]. Liu WS, Hsin CH, Chou YH, et al. Long-term results of
intensity-modulated radiotherapy concomitant with chemotherapy for
hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer.
2010; 10:102.
[21]. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of the head and neck. N Engl J
Med. 2006; 354(6):567-578.
[22]. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for locoregionally advanced head and neck cancer: 5-year
survival data from a phase 3 randomised trial, and relation between
cetuximab-induced rash and survival. Lancet Oncol. 2010; 11(1):21-28.
[23]. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally
advanced head and neck cancer treated with primary radiotherapy: a
comparison of the addition of cetuximab or chemotherapy and the impact
of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;
71(3):676-681.
[24]. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a
promising therapeutic monoclonal for treatment of tumors of epithelial
origin. MAbs. 2009; 1(1):41-48.
[25]. Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation
of U87MG brain tumours by anti-epidermal growth factor receptor
monoclonal antibodies. Br J Cancer. 2009; 100(6):950-958.